Skip to main content
Top
Published in: Journal of Nephrology 1/2018

Open Access 01-02-2018 | Original Article

Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study

Authors: Laura Girardat-Rotar, Milo A. Puhan, Julia Braun, Andreas L. Serra

Published in: Journal of Nephrology | Issue 1/2018

Login to get access

Abstract

Background

Previous in vitro experiments of human polycystic kidney disease (PKD) cells reported that caffeine is a risk factor for the promotion of cyst enlargement in patients with autosomal dominant PKD (ADPKD). The relentless progression of ADPKD inclines the majority of physicians to advocate minimization of caffeine consumption despite the absence of clinical data supporting such a recommendation so far. This is the first clinical study to assess prospectively the association between coffee consumption and disease progression in a longitudinal ADPKD cohort.

Methods

Information on coffee consumption and disease progression was collected at each follow-up visit using standardized measurement methods. The main model for the outcomes, kidney size (height-adjusted total kidney volume, htTKV) and kidney function (estimated glomerular filtration rate, eGFR), was a linear mixed model. Patients entered the on-going Swiss ADPKD study between 2006 and June 2014 and had at least 1 visit every year. The sample size of the study population was 151 with a median follow-up of 4 visits per patient and a median follow-up time of 4.38 years.

Results

After multivariate adjustment for age, smoking, hypertension, sex, body mass index and an interaction term (coffee*visit), coffee drinkers did not have a statistically significantly different kidney size compared to non-coffee drinkers (difference of −33.03 cm3 height adjusted TKV, 95% confidence interval (CI) from −72.41 to 6.34, p = 0.10). After the same adjustment, there was no statistically significant difference in eGFR between coffee and non-coffee drinkers (2.03 ml/min/1.73 m2, 95% CI from −0.31 to 4.31, p = 0.089).

Conclusion

Data derived from our prospective longitudinal study do not confirm that drinking coffee is a risk factor for ADPKD progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ (2002) The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13(11):2723–2729CrossRefPubMed Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ (2002) The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13(11):2723–2729CrossRefPubMed
2.
go back to reference Ars E, Bernis C, Fraga G, Martinez V, Martins J, Ortiz A, Rodriguez-Perez JC, Sans L, Torra R, Spanish Working Group on Inherited Kidney D (2014) Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 29(Suppl 4):iv95–i105. doi:10.1093/ndt/gfu186 CrossRefPubMed Ars E, Bernis C, Fraga G, Martinez V, Martins J, Ortiz A, Rodriguez-Perez JC, Sans L, Torra R, Spanish Working Group on Inherited Kidney D (2014) Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 29(Suppl 4):iv95–i105. doi:10.​1093/​ndt/​gfu186 CrossRefPubMed
5.
go back to reference Vendramini LC, Nishiura JL, Baxmann AC, Heilberg IP (2012) Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz J Med Biol Res 45(9):834–840CrossRefPubMedPubMedCentral Vendramini LC, Nishiura JL, Baxmann AC, Heilberg IP (2012) Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz J Med Biol Res 45(9):834–840CrossRefPubMedPubMedCentral
6.
go back to reference Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference P (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88(1):17–27. doi:10.1038/ki.2015.59 CrossRefPubMedPubMedCentral Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference P (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88(1):17–27. doi:10.​1038/​ki.​2015.​59 CrossRefPubMedPubMedCentral
7.
go back to reference Crippa A, Discacciati A, Larsson SC, Wolk A, Orsini N (2014) Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. Am J Epidemiol 180(8):763–775. doi:10.1093/aje/kwu194 CrossRefPubMed Crippa A, Discacciati A, Larsson SC, Wolk A, Orsini N (2014) Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. Am J Epidemiol 180(8):763–775. doi:10.​1093/​aje/​kwu194 CrossRefPubMed
11.
go back to reference Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. doi:10.1056/NEJMoa0907419 PubMed Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. doi:10.​1056/​NEJMoa0907419 PubMed
12.
go back to reference Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wuethrich RP, Serra AL (2009) Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75(2):235–241. doi:10.1038/ki.2008.558 CrossRefPubMed Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wuethrich RP, Serra AL (2009) Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75(2):235–241. doi:10.​1038/​ki.​2008.​558 CrossRefPubMed
14.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612 pii]CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612 pii]CrossRefPubMedPubMedCentral
15.
16.
go back to reference Hsu YC, Lee PH, Lei CC, Shih YH, Lin CL (2014) Analgesic use, parents’ clan, and coffee intake are three independent risk factors of chronic kidney disease in middle and elderly-aged population: a community-based study. Ren Fail 36(3):361–366. doi:10.3109/0886022X.2013.866017 CrossRefPubMed Hsu YC, Lee PH, Lei CC, Shih YH, Lin CL (2014) Analgesic use, parents’ clan, and coffee intake are three independent risk factors of chronic kidney disease in middle and elderly-aged population: a community-based study. Ren Fail 36(3):361–366. doi:10.​3109/​0886022X.​2013.​866017 CrossRefPubMed
19.
go back to reference Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM (2005) Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 23(5):921–928CrossRefPubMed Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM (2005) Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 23(5):921–928CrossRefPubMed
21.
go back to reference Jee SH, He J, Appel LJ, Whelton PK, Suh I, Klag MJ (2001) Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol 153(4):353–362CrossRefPubMed Jee SH, He J, Appel LJ, Whelton PK, Suh I, Klag MJ (2001) Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol 153(4):353–362CrossRefPubMed
23.
go back to reference Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31 (3):337–348. doi:10.1093/ndt/gfv456 CrossRefPubMedPubMedCentral Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31 (3):337–348. doi:10.​1093/​ndt/​gfv456 CrossRefPubMedPubMedCentral
Metadata
Title
Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study
Authors
Laura Girardat-Rotar
Milo A. Puhan
Julia Braun
Andreas L. Serra
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 1/2018
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-017-0396-8

Other articles of this Issue 1/2018

Journal of Nephrology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine